Dextromethorphan Bupropion
Auvelity is a brand-name oral medication combining dextromethorphan and bupropion, used to treat major depressive disorder (MDD) in adults. Dextromethorphan acts on brain glutamate receptors and sigma receptors, while bupropion increases norepinephrine and dopamine levels; bupropion also helps maintain dextromethorphan concentrations by inhibiting its breakdown. This combination provides an alternative mechanism for patients who haven't responded to traditional antidepressants.
Auvelity is a prescription brand-name antidepressant for adults with major depressive disorder, combining two medications with complementary mechanisms of action.
Key facts at a glance
- RxNorm
- 2611261
- Generic
- Auvelity
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Auvelity is FDA-approved for the treatment of major depressive disorder (MDD) in adults. It is specifically indicated for patients seeking an alternative to conventional first-line antidepressants.
Auvelity combines dextromethorphan (an NMDA receptor antagonist and sigma-1 receptor agonist) with bupropion (a norepinephrine-dopamine reuptake inhibitor). Bupropion inhibits the CYP2D6 enzyme that normally metabolizes dextromethorphan, allowing therapeutic levels to be maintained. Together, they modulate glutamate signaling and monoamine neurotransmitters to improve mood.
Common side effects may include dizziness, headache, dry mouth, and sexual dysfunction. Caution is advised in patients with seizure disorders, eating disorders, or those using MAOIs. It should not be used in combination with monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping them. Patients should be monitored for worsening depression or suicidal thoughts, particularly when starting treatment.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed September 2, 2026. · Read our editorial policy